Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
Sems LloydDirector
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082600 · tm2119990d4_4.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
BARKER SAM LDirector
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082604 · tm2119990d6_4.xml · derivative · entry 2 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
BARKER SAM LDirector
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082604 · tm2119990d6_4.xml · nonDerivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,386 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082602 · tm2119990d5_4.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
Spiegel Robert J.Director
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082602 · tm2119990d5_4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082599 · tm2119990d3_4.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082599 · tm2119990d3_4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
SCHWARTZ BRIANDirector
|
GrantStock Option (right to buy) · Derivative | 2,374 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082597 · tm2119990d1_4.xml · derivative · entry 4 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 2,374 shares Expires 2031-06-15 F3 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
SCHWARTZ BRIANDirector
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082597 · tm2119990d1_4.xml · derivative · entry 3 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F3 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
SCHWARTZ BRIANDirector
|
GrantCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082597 · tm2119990d1_4.xml · nonDerivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F2 · shares: The reporting person received an award of 1,187 restricted stock units on June 15, 2021, which shall vest in three equal installments on June 15, 2022, June 15, 2023, and June 15, 2024. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
SCHWARTZ BRIANDirector
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082597 · tm2119990d1_4.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
Walker Karin LDirector
|
GrantStock Option (right to buy) · Derivative | 2,374 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 2,374 shares Expires 2031-06-15 F3 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
Walker Karin LDirector
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F3 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
Walker Karin LDirector
|
GrantCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F2 · shares: The reporting person received an award of 1,187 restricted stock units on June 15, 2021, which shall vest in three equal installments on June 15, 2022, June 15, 2023, and June 15, 2024. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:07 UTC |
Walker Karin LDirector
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082598 · tm2119990d2_4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:48 UTC |
SCHWARTZ BRIANDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001104659-20-138095 · tm2039008-2_4seq1.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-12-17 F1 · security: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:25 UTC |
McBarron PaulDirector · See Remarks
|
GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001104659-20-135750 · tm2038414d2_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-12-11 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:25 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001104659-20-135749 · tm2038414d1_4.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-11 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 13:45 UTC |
Walker Karin LDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001104659-20-124026 · tm2035660d2_4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-11-09 F1 · security: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 20:12 UTC |
Kirschbaum MarkChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001104659-20-118939 · tm2034345d2_4.xml · derivative · entry 1 Kirschbaum Mark · CIK 0001830211 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-10-23 F1 · derivative.exercise_date: The shares underlying this option vest as to 40,000 shares on October 23, 2021, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:51 UTC |
Sems LloydDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078132 · tm2023597-8_4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:51 UTC |
Banham John Michael MiddlecottDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078131 · tm2023597-7_4.xml · derivative · entry 1 Banham John Michael Middlecott · CIK 0001357635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Sir John Banham for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:50 UTC |
Hradsky Gregory T.Director
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078129 · tm2023597-6_4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:50 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078125 · tm2023597d5_4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:49 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078123 · tm2023597d4_form4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:49 UTC |
UPRICHARD DAVID CDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078122 · tm2023597d3_form4.xml · derivative · entry 1 UPRICHARD DAVID C · CIK 0001239916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Dr. U'Prichard for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:48 UTC |
BARKER SAM LDirector
|
GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078120 · tm2023597d2_form4.xml · derivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:01 UTC |
Chiao JudyV.P., Clin. Dev. & Reg. Aff.
|
GrantOption · Derivative | 10,182 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-19-071121 · tm1924755d3_4.xml · derivative · entry 2 Chiao Judy · CIK 0001357601 · V.P., Clin. Dev. & Reg. Aff. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,182 Underlying: Common Stock · 10,182 shares Expires 2028-02-22 F2 · price: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 10,182 shares. F2 · derivative.exercise_date: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 10,182 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:01 UTC |
Chiao JudyV.P., Clin. Dev. & Reg. Aff.
|
GrantOption · Derivative | 11,067 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-19-071121 · tm1924755d3_4.xml · derivative · entry 1 Chiao Judy · CIK 0001357601 · V.P., Clin. Dev. & Reg. Aff. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,067 Underlying: Common Stock · 11,067 shares Expires 2027-12-29 F1 · price: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,067 shares. F1 · derivative.exercise_date: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,067 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:01 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantOption · Derivative | 15,625 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-19-071120 · tm1924755d2_4.xml · derivative · entry 2 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2028-02-22 F2 · price: On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 15,625 shares. F2 · derivative.exercise_date: On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 15,625 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:01 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantOption · Derivative | 15,625 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-19-071120 · tm1924755d2_4.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2027-12-29 F1 · price: On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 15,625 shares. F1 · derivative.exercise_date: On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 15,625 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:00 UTC |
McBarron PaulDirector · E. VP, Fin, CFO and COO
|
GrantOption · Derivative | 11,980 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-19-071119 · tm1924755d1_4.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,980 Underlying: Common Stock · 11,980 shares Expires 2028-02-22 F2 · price: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares. F2 · derivative.exercise_date: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:00 UTC |
McBarron PaulDirector · E. VP, Fin, CFO and COO
|
GrantOption · Derivative | 13,022 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-19-071119 · tm1924755d1_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,022 Underlying: Common Stock · 13,022 shares Expires 2027-12-29 F1 · price: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares. F1 · derivative.exercise_date: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:36 UTC |
BARKER SAM LDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029254 · tv522819_form4.xml · derivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:37 UTC |
Sems LloydDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029256 · tv522821_form4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:40 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029261 · tv522828_form4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:40 UTC |
Hradsky Gregory T.Director
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029260 · tv522827_form4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:39 UTC |
Banham John Michael MiddlecottDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029259 · tv522825_form4.xml · derivative · entry 1 Banham John Michael Middlecott · CIK 0001357635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Sir John Banham for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:39 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029258 · tv522822_form4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:37 UTC |
UPRICHARD DAVID CDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029255 · tv522820_form4.xml · derivative · entry 1 UPRICHARD DAVID C · CIK 0001239916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Dr. U'Prichard for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 14:26 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantOption · Derivative | 508,198 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001144204-19-000788 · tv510488_4.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,198 Underlying: Common Stock · 508,198 shares Expires 2029-01-04 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 14:28 UTC |
McBarron PaulDirector · E. VP, Fin, CFO and COO
|
GrantOption · Derivative | 270,079 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,079 Underlying: Common Stock · 270,079 shares Expires 2029-01-04 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 14:27 UTC |
Chiao JudyV.P., Clin. Dev. & Reg. Aff
|
GrantOption · Derivative | 284,592 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001144204-19-000789 · tv510489_4.xml · derivative · entry 1 Chiao Judy · CIK 0001357601 · V.P., Clin. Dev. & Reg. Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,592 Underlying: Common Stock · 284,592 shares Expires 2029-01-04 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:26 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantOption · Derivative | 14,375 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001144204-19-000788 · tv510488_4.xml · derivative · entry 3 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 Underlying: Common Stock · 14,375 shares Expires 2028-02-22 F4 · price: On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares. F4 · derivative.exercise_date: On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:26 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantOption · Derivative | 15,625 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-19-000788 · tv510488_4.xml · derivative · entry 2 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2027-12-29 F3 · price: On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares. F3 · derivative.exercise_date: On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:28 UTC |
McBarron PaulDirector · E. VP, Fin, CFO and COO
|
GrantOption · Derivative | 11,980 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 3 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,980 Underlying: Common Stock · 11,980 shares Expires 2028-02-22 F4 · price: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares. F4 · derivative.exercise_date: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:28 UTC |
McBarron PaulDirector · E. VP, Fin, CFO and COO
|
GrantOption · Derivative | 13,021 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021 Underlying: Common Stock · 13,021 shares Expires 2027-12-29 F3 · price: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares. F3 · derivative.exercise_date: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:27 UTC |
Chiao JudyV.P., Clin. Dev. & Reg. Aff
|
GrantOption · Derivative | 10,183 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001144204-19-000789 · tv510489_4.xml · derivative · entry 3 Chiao Judy · CIK 0001357601 · V.P., Clin. Dev. & Reg. Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,183 Underlying: Common Stock · 10,183 shares Expires 2028-02-22 F4 · price: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 10,183 shares. F4 · derivative.exercise_date: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 10,183 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:27 UTC |
Chiao JudyV.P., Clin. Dev. & Reg. Aff
|
GrantOption · Derivative | 11,068 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-19-000789 · tv510489_4.xml · derivative · entry 2 Chiao Judy · CIK 0001357601 · V.P., Clin. Dev. & Reg. Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,068 Underlying: Common Stock · 11,068 shares Expires 2027-12-29 F3 · price: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,068 shares. F3 · derivative.exercise_date: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,068 shares. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 12:44 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 8,576 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001144204-18-048729 · tv502611_4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,576 Underlying: Common Stock · 8,576 shares Expires 2028-09-06 F1 · price: These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.